CN102131783A - 作为axl激酶抑制剂的喹啉衍生物 - Google Patents
作为axl激酶抑制剂的喹啉衍生物 Download PDFInfo
- Publication number
- CN102131783A CN102131783A CN2009801129869A CN200980112986A CN102131783A CN 102131783 A CN102131783 A CN 102131783A CN 2009801129869 A CN2009801129869 A CN 2009801129869A CN 200980112986 A CN200980112986 A CN 200980112986A CN 102131783 A CN102131783 A CN 102131783A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- fluoro
- quinolyl
- oxygen base
- dimethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 COc1cc2c(*c(cc3)cc(F)c3NS(c3cc(Cl)cc(Cl)c3)(=O)=O)ccnc2cc1OC Chemical compound COc1cc2c(*c(cc3)cc(F)c3NS(c3cc(Cl)cc(Cl)c3)(=O)=O)ccnc2cc1OC 0.000 description 3
- RNKITPKDGNVIQD-UHFFFAOYSA-N CC(C(c1c2)Oc(cc3)c(C)cc3NS(c(cc3)c(cccc4)c4c3OC)(=O)=O)C=Nc1cc(OC)c2OC Chemical compound CC(C(c1c2)Oc(cc3)c(C)cc3NS(c(cc3)c(cccc4)c4c3OC)(=O)=O)C=Nc1cc(OC)c2OC RNKITPKDGNVIQD-UHFFFAOYSA-N 0.000 description 1
- UYKJAMOSSBXCGJ-UHFFFAOYSA-N CC(c(cccc1)c1S(Nc(cc1)cc(F)c1Oc1c(cc(c(OCCCN)c2)OC)c2ncc1)(=O)=O)(F)F Chemical compound CC(c(cccc1)c1S(Nc(cc1)cc(F)c1Oc1c(cc(c(OCCCN)c2)OC)c2ncc1)(=O)=O)(F)F UYKJAMOSSBXCGJ-UHFFFAOYSA-N 0.000 description 1
- QGWANWMXPLJGCH-UHFFFAOYSA-N CCCS(Cc(cc1)cc(F)c1Oc1c(cc(c(OCCCN2CCC(C)CC2)c2)OC)c2ncc1)(=O)=O Chemical compound CCCS(Cc(cc1)cc(F)c1Oc1c(cc(c(OCCCN2CCC(C)CC2)c2)OC)c2ncc1)(=O)=O QGWANWMXPLJGCH-UHFFFAOYSA-N 0.000 description 1
- NIEBODPRPFUYPU-UHFFFAOYSA-N CCc1cc2cccc(Oc(ccc(NS(c3cccc(Oc4ccccc4)c3)(=O)=O)c3)c3F)c2cc1OC Chemical compound CCc1cc2cccc(Oc(ccc(NS(c3cccc(Oc4ccccc4)c3)(=O)=O)c3)c3F)c2cc1OC NIEBODPRPFUYPU-UHFFFAOYSA-N 0.000 description 1
- ROWGSKQMKOFDSC-UHFFFAOYSA-N CNc(cc(c1c2)[IH][I]=CC=C1Oc(cc1)cc(F)c1NS(c(cc1)c(cccc3)c3c1OC)(=O)=O)c2OC Chemical compound CNc(cc(c1c2)[IH][I]=CC=C1Oc(cc1)cc(F)c1NS(c(cc1)c(cccc3)c3c1OC)(=O)=O)c2OC ROWGSKQMKOFDSC-UHFFFAOYSA-N 0.000 description 1
- ZHICDYCCWSHRHV-UHFFFAOYSA-N COc(c(OC)cc1ncc2)cc1c2Oc(cc1)cc(F)c1NS(c(cccc1)c1N)(=O)=O Chemical compound COc(c(OC)cc1ncc2)cc1c2Oc(cc1)cc(F)c1NS(c(cccc1)c1N)(=O)=O ZHICDYCCWSHRHV-UHFFFAOYSA-N 0.000 description 1
- LIIIKKJBUCTUNP-UHFFFAOYSA-N COc(ccc(Cl)c1)c1S(Nc(cc1)ccc1Oc1c(cc(c(OC)c2)OC)c2ncc1)(=O)=O Chemical compound COc(ccc(Cl)c1)c1S(Nc(cc1)ccc1Oc1c(cc(c(OC)c2)OC)c2ncc1)(=O)=O LIIIKKJBUCTUNP-UHFFFAOYSA-N 0.000 description 1
- UPDPHLWJXBYILK-UHFFFAOYSA-N Cc([nH]1)ncc1S(Nc(cc1)ccc1Oc1c(cc(c(OC)c2)OC)c2ncc1)(=O)=O Chemical compound Cc([nH]1)ncc1S(Nc(cc1)ccc1Oc1c(cc(c(OC)c2)OC)c2ncc1)(=O)=O UPDPHLWJXBYILK-UHFFFAOYSA-N 0.000 description 1
- SACCQJZNCZRVFV-UHFFFAOYSA-N Cc(cc(c1c2)Oc(cc3)ccc3NS(c3cc(Cl)cc(N)c3OC)(=O)=O)nc1ccc2F Chemical compound Cc(cc(c1c2)Oc(cc3)ccc3NS(c3cc(Cl)cc(N)c3OC)(=O)=O)nc1ccc2F SACCQJZNCZRVFV-UHFFFAOYSA-N 0.000 description 1
- LGCWFJPSZYDDGE-UHFFFAOYSA-N Cc(cc(cc1)Oc2c(cc(c(OC)c3)OC)c3ncc2)c1NS(c1c(C(F)(F)F)cccc1)(=O)=O Chemical compound Cc(cc(cc1)Oc2c(cc(c(OC)c3)OC)c3ncc2)c1NS(c1c(C(F)(F)F)cccc1)(=O)=O LGCWFJPSZYDDGE-UHFFFAOYSA-N 0.000 description 1
- CDGAWYXJDLVXDH-UHFFFAOYSA-N Cc1cc(S(Nc(c(F)c2)ccc2OC2=CC=NC(C3)C2=CC(OC)=C3OC)(=O)=O)cc(F)c1 Chemical compound Cc1cc(S(Nc(c(F)c2)ccc2OC2=CC=NC(C3)C2=CC(OC)=C3OC)(=O)=O)cc(F)c1 CDGAWYXJDLVXDH-UHFFFAOYSA-N 0.000 description 1
- UTWQBHFTQJWFTQ-UHFFFAOYSA-N Cc1cc(c(C(F)(F)F)ccc2)c2c(Oc(cc2)cc(F)c2NS(c2cccc3c2cccc3)(=O)=O)c1 Chemical compound Cc1cc(c(C(F)(F)F)ccc2)c2c(Oc(cc2)cc(F)c2NS(c2cccc3c2cccc3)(=O)=O)c1 UTWQBHFTQJWFTQ-UHFFFAOYSA-N 0.000 description 1
- IMLNGKAJJBDEHO-UHFFFAOYSA-N Cc1nc2c(C(F)(F)F)cccc2c(Oc(cc2)cc(F)c2N[IH]S(c(cc2Cl)ccc2I)(=O)=O)c1 Chemical compound Cc1nc2c(C(F)(F)F)cccc2c(Oc(cc2)cc(F)c2N[IH]S(c(cc2Cl)ccc2I)(=O)=O)c1 IMLNGKAJJBDEHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4539808P | 2008-04-16 | 2008-04-16 | |
| US61/045,398 | 2008-04-16 | ||
| PCT/EP2009/002798 WO2009127417A1 (en) | 2008-04-16 | 2009-04-16 | Quinoline derivatives as axl kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102131783A true CN102131783A (zh) | 2011-07-20 |
Family
ID=40999731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801129869A Pending CN102131783A (zh) | 2008-04-16 | 2009-04-16 | 作为axl激酶抑制剂的喹啉衍生物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9206130B2 (https=) |
| EP (1) | EP2262772B8 (https=) |
| JP (1) | JP5746015B2 (https=) |
| KR (1) | KR101325237B1 (https=) |
| CN (1) | CN102131783A (https=) |
| AU (1) | AU2009237938A1 (https=) |
| CA (1) | CA2718538A1 (https=) |
| ES (1) | ES2391373T3 (https=) |
| IL (1) | IL208103A (https=) |
| MX (1) | MX2010011224A (https=) |
| RU (1) | RU2010146474A (https=) |
| WO (1) | WO2009127417A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103958497A (zh) * | 2011-11-14 | 2014-07-30 | 赛福伦公司 | 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物 |
| WO2018121228A1 (zh) * | 2016-12-28 | 2018-07-05 | 中国科学院上海药物研究所 | 一种具有axl抑制活性的化合物及其制备和应用 |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| EP2423208A1 (en) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| ITRM20100537A1 (it) | 2010-10-12 | 2012-04-12 | Consiglio Nazionale Ricerche | Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia |
| DK2810937T3 (en) | 2012-01-31 | 2017-03-13 | Daiichi Sankyo Co Ltd | PYRIDONE DERIVATIVES |
| EP3184121A3 (en) | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases |
| TWI649308B (zh) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| AU2014353006B2 (en) | 2013-11-20 | 2019-04-04 | Signalchem Life Sciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
| WO2015077550A1 (en) * | 2013-11-22 | 2015-05-28 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| US10233176B2 (en) | 2013-11-27 | 2019-03-19 | Signalchem Lifesciences Corporation | Aminopyridine derivatives as TAM family kinase inhibitors |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| ES2749726T3 (es) * | 2014-12-25 | 2020-03-23 | Ono Pharmaceutical Co | Derivado de quinolina |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| WO2017146236A1 (ja) | 2016-02-26 | 2017-08-31 | 小野薬品工業株式会社 | Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
| KR102483020B1 (ko) | 2016-03-28 | 2023-01-04 | 인사이트 코포레이션 | Tam 저해제로서의 피롤로트리아진 화합물 |
| TWI779007B (zh) | 2017-01-26 | 2022-10-01 | 日商小野藥品工業股份有限公司 | 喹啉衍生物的乙磺酸鹽 |
| US20200197385A1 (en) | 2017-08-23 | 2020-06-25 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for cancer containing axl inhibitor as active ingredient |
| TW201920104A (zh) * | 2017-08-31 | 2019-06-01 | 美商馬愈法瑪公司 | 外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制劑及其用途 |
| MA50655B1 (fr) | 2017-09-27 | 2021-11-30 | Incyte Corp | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam |
| US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
| AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| JP2023525757A (ja) * | 2020-05-08 | 2023-06-19 | ジョージアミューン・インコーポレイテッド | Ａｋｔ３モジュレーター |
| JP2022104746A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗がん剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| ATE356117T1 (de) * | 1999-01-22 | 2007-03-15 | Kirin Brewery | Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| EP1566379A4 (en) * | 2002-10-29 | 2005-11-09 | Kirin Brewery | CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF |
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| CA2619037A1 (en) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| PL2101759T3 (pl) * | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
-
2009
- 2009-04-16 RU RU2010146474/04A patent/RU2010146474A/ru not_active Application Discontinuation
- 2009-04-16 EP EP09731679A patent/EP2262772B8/en active Active
- 2009-04-16 JP JP2011504377A patent/JP5746015B2/ja active Active
- 2009-04-16 CA CA2718538A patent/CA2718538A1/en not_active Abandoned
- 2009-04-16 ES ES09731679T patent/ES2391373T3/es active Active
- 2009-04-16 MX MX2010011224A patent/MX2010011224A/es not_active Application Discontinuation
- 2009-04-16 US US12/933,070 patent/US9206130B2/en active Active
- 2009-04-16 AU AU2009237938A patent/AU2009237938A1/en not_active Abandoned
- 2009-04-16 WO PCT/EP2009/002798 patent/WO2009127417A1/en not_active Ceased
- 2009-04-16 KR KR1020107023097A patent/KR101325237B1/ko active Active
- 2009-04-16 CN CN2009801129869A patent/CN102131783A/zh active Pending
-
2010
- 2010-09-13 IL IL208103A patent/IL208103A/en active IP Right Grant
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103958497A (zh) * | 2011-11-14 | 2014-07-30 | 赛福伦公司 | 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物 |
| US9120778B2 (en) | 2011-11-14 | 2015-09-01 | Ignyta, Inc. | Uracil derivatives as AXL and c-MET kinase inhibitors |
| US9522902B2 (en) | 2011-11-14 | 2016-12-20 | Ignyta, Inc. | Uracil derivatives as AXL and c-MET kinase inhibitors |
| TWI562989B (en) * | 2011-11-14 | 2016-12-21 | Ignyta Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| US9745283B2 (en) | 2011-11-14 | 2017-08-29 | Ignyta, Inc. | Uracil derivatives as AXL and c-MET kinase inhibitors |
| CN103958497B (zh) * | 2011-11-14 | 2017-09-01 | 亚尼塔公司 | 作为AXL和c‑MET激酶抑制剂的尿嘧啶衍生物 |
| US10017496B2 (en) | 2011-11-14 | 2018-07-10 | Ignyta, Inc. | Uracil derivatives as AXL and c-MET kinase inhibitors |
| WO2018121228A1 (zh) * | 2016-12-28 | 2018-07-05 | 中国科学院上海药物研究所 | 一种具有axl抑制活性的化合物及其制备和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010011224A (es) | 2011-02-25 |
| EP2262772A1 (en) | 2010-12-22 |
| RU2010146474A (ru) | 2012-05-27 |
| IL208103A (en) | 2015-08-31 |
| US9206130B2 (en) | 2015-12-08 |
| KR20100132038A (ko) | 2010-12-16 |
| JP5746015B2 (ja) | 2015-07-08 |
| EP2262772B1 (en) | 2012-07-18 |
| JP2011517689A (ja) | 2011-06-16 |
| WO2009127417A1 (en) | 2009-10-22 |
| US20110092503A1 (en) | 2011-04-21 |
| EP2262772B8 (en) | 2013-03-13 |
| KR101325237B1 (ko) | 2013-11-04 |
| IL208103A0 (en) | 2010-12-30 |
| CA2718538A1 (en) | 2009-10-22 |
| AU2009237938A1 (en) | 2009-10-22 |
| ES2391373T3 (es) | 2012-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2262772B1 (en) | Quinoline derivatives as axl kinase inhibitors | |
| EP1415987B1 (en) | Nitrogenous aromatic ring compounds as anti cancer agents | |
| CN102317269B (zh) | 新氨基氮杂杂环甲酰胺类 | |
| ES2868355T3 (es) | Inhibidores del bromodominio | |
| RU2497809C2 (ru) | Производные нафталинкарбоксамида в качестве ингибиторов протеинкиназы и гистондеацетилазы, способы их получения и применение | |
| CN102977014B (zh) | 新的喹啉类化合物及其用途 | |
| CN107056755B (zh) | 五元杂环酰胺类wnt通路抑制剂 | |
| WO2018145621A1 (zh) | 喹啉类化合物、其制备方法及其医药用途 | |
| CN107098846A (zh) | N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途 | |
| US20250136580A1 (en) | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | |
| CN110684013A (zh) | 含3-哒嗪酮、4-哒嗪酮和1,2,4-三嗪酮结构的4-苯氧基吡啶类衍生物及其应用 | |
| CN114763360A (zh) | 手性大环化合物作为蛋白激酶抑制剂及其用途 | |
| TW201934547A (zh) | 一種嘧啶類化合物、其製備方法及其醫藥用途 | |
| HK1156952A (en) | Quinoline derivatives as axl kinase inhibitors | |
| CN102558144A (zh) | 一种芳基脲衍生物 | |
| CN105263926B (zh) | 苯并噻吩化合物 | |
| KR20060123330A (ko) | 키나제 장애의 치료에 유용한 아미노치환 피리디닐 메타논화합물 | |
| US20200148676A1 (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| CN103052641B (zh) | 作为c‑Met抑制剂的新型稠环杂环衍生物 | |
| CN117343046A (zh) | 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用 | |
| CN102850280B (zh) | 6,7-二烷氧基-4-取代苯基氨基喹唑啉类化合物及其制备方法 | |
| HK1166070B (en) | Novel amino azaheterocyclic carboxamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1156952 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110720 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1156952 Country of ref document: HK |